AU2022312764A1 - Cannabidiolic acid esters for treating prader-willi syndrome - Google Patents

Cannabidiolic acid esters for treating prader-willi syndrome Download PDF

Info

Publication number
AU2022312764A1
AU2022312764A1 AU2022312764A AU2022312764A AU2022312764A1 AU 2022312764 A1 AU2022312764 A1 AU 2022312764A1 AU 2022312764 A AU2022312764 A AU 2022312764A AU 2022312764 A AU2022312764 A AU 2022312764A AU 2022312764 A1 AU2022312764 A1 AU 2022312764A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
use according
group
cannabinoid
thc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022312764A
Other languages
English (en)
Inventor
Ron SHAHRABANI
Rotem SHER
Reshef SWISA
Joseph Tam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Epm Ip Inc
Original Assignee
Epm Ip Inc
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epm Ip Inc, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Epm Ip Inc
Publication of AU2022312764A1 publication Critical patent/AU2022312764A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2022312764A 2021-07-13 2022-07-07 Cannabidiolic acid esters for treating prader-willi syndrome Pending AU2022312764A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163221006P 2021-07-13 2021-07-13
US63/221,006 2021-07-13
US202163276668P 2021-11-08 2021-11-08
US63/276,668 2021-11-08
PCT/IL2022/050734 WO2023286047A1 (en) 2021-07-13 2022-07-07 Cannabidiolic acid esters for treating prader-willi syndrome

Publications (1)

Publication Number Publication Date
AU2022312764A1 true AU2022312764A1 (en) 2024-01-18

Family

ID=84919088

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022312764A Pending AU2022312764A1 (en) 2021-07-13 2022-07-07 Cannabidiolic acid esters for treating prader-willi syndrome

Country Status (7)

Country Link
US (1) US20240316073A1 (https=)
EP (1) EP4370106A4 (https=)
JP (1) JP2024528569A (https=)
AU (1) AU2022312764A1 (https=)
CA (1) CA3224271A1 (https=)
IL (1) IL310009A (https=)
WO (1) WO2023286047A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3062814C (en) * 2017-04-27 2023-11-14 Insys Development Company, Inc. Stable cannabinoid formulations
US12403114B2 (en) * 2019-03-12 2025-09-02 Epm (Ip), Inc. Cannabinoid acid ester compositions and uses thereof
WO2021137224A1 (en) * 2020-01-01 2021-07-08 Epm Group, Inc. Cannabidiolic acid esters for treating muscular dystrophy
CN113087599A (zh) * 2020-01-08 2021-07-09 成都百裕制药股份有限公司 大麻二酚衍生物及其制备方法和在医药上的应用

Also Published As

Publication number Publication date
IL310009A (en) 2024-03-01
JP2024528569A (ja) 2024-07-30
US20240316073A1 (en) 2024-09-26
WO2023286047A1 (en) 2023-01-19
EP4370106A1 (en) 2024-05-22
EP4370106A4 (en) 2025-05-21
CA3224271A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
US9980980B2 (en) Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
BR112015015870B1 (pt) Uso de uma composição farmacêutica
CA3132637A1 (en) Cannabinoid acid ester compositions and uses thereof
JP3114895B2 (ja) 炎症性疾患の処置のための薬剤調製物
CN102274227B (zh) 粉防己碱在制备预防和/或治疗抑郁症药物中的应用
JP4261337B2 (ja) リパーゼ阻害剤とショ糖脂肪酸エステルとを含む医薬組成物
JP7352623B2 (ja) 抗うつ製品の製造におけるヒドロキシチロソールおよびその誘導体の新規使用
WO2021224924A1 (en) Cannabidiolic acid esters for treating respiratory distress including acute respiratory distress syndrome and coronavirus
US20240316073A1 (en) Cannabidiolic acid esters for treating prader-willi syndrome
CN117813081A (zh) 用于治疗普拉德-威利综合征的大麻二醇酸酯
WO2021137224A1 (en) Cannabidiolic acid esters for treating muscular dystrophy
HK40107023A (zh) 用於治疗普拉德-威利综合征的大麻二醇酸酯
EP3642215B1 (en) Crystalline forms of beta-sitosterol
EP4479412B1 (en) Dhea-derived steroids
CN101967174A (zh) 一种环木菠萝烯醇阿魏酸酯的组合物制剂和纯化工艺
CN121868281A (zh) 三萜皂苷类化合物和神经酸在制备防治帕金森病及其症状的药物中的应用
WO2010136592A1 (en) Derivatives of ursodeoxycholic acid for the treatment of diarrhoea
JP2019507792A (ja) 関節リウマチを治療および予防するための組成物